Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients |
| |
Authors: | Emilio Bajetta Maria Di Bartolomeo Roberto Buzzoni Erminia Ferrario Katia F Dotti Luigi Mariani Roberto Bajetta Arpine Gevorgyan Paola Venturino Margherita Galassi |
| |
Institution: | (1) Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian, 20133 Milan, Italy;(2) Statistics and Biometry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;(3) Hospital Pharmacy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;(4) F. Hoffman-La Roche, Monza, Italy |
| |
Abstract: | Purpose This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan
and capecitabine in pre-treated metastatic colorectal cancer patients.
Methods Five dose level combinations with irinotecan (from 180 to 240 mg/m2, day 1, q21), capecitabine (1,500–2,000 mg/m2 per day, days 2–15, q21) and erlotinib (50–150 mg per day, continuously) were planned. Patients were enrolled in cohorts
of three, and evaluated for first cycle acute toxicity.
Results Twenty-one patients were treated. In the first cohort, no DLT was reported, in the second: one DLT (G4 neutropenic fever associated
with G3 cutaneous rash and mucositis); in the third dose level: two DLT (G3 diarrhea and G4 neutropenic fever). To confirm
these results, other six patients were additionally included and no DLT was observed.
Conclusions The results documented that erlotinib at the dose of 100 mg per day, irinotecan 180 mg/m2 and capecitabine 1,500 mg/m2 per day for 14 days has an acceptable safety profile and appears suitable for further phase II studies. |
| |
Keywords: | Erlotinib Irinotecan Capecitabine Colorectal cancer |
本文献已被 PubMed SpringerLink 等数据库收录! |
|